Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
43 hedge funds and large institutions have $88.8M invested in Astria Therapeutics in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 2 closing their positions.
3,150% more call options, than puts
Call options by funds: $130K | Put options by funds: $4K
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
417% more capital invested
Capital invested by funds: $17.2M → $88.8M (+$71.7M)
43% more funds holding
Funds holding: 30 → 43 (+13)
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
31.46% more ownership
Funds ownership: 44.03% → 75.49% (+31%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$6.7M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.03M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$4.4M |
| 4 |
TLP
Tri Locum Partners
New York
|
+$4.23M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$3.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.28M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$653K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$531K |
| 4 |
OC
Oppenheimer & Co
New York
|
-$38.9K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$19.6K |
ATXS Hedge Fund Activity: Q3 2022 in Review
43 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2022, worth a combined $88.8M — up 417% from $17.2M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ATXS positions and 2 closed out — a net gain of 13 holders — while 11 added to existing stakes and 8 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $6.7M. The largest seller was RA Capital Management, exiting entirely with an estimated $2.28M sold.
- 43 institutional investors held Astria Therapeutics (ATXS) as of Q3 2022, up from 30 in Q2 2022.
- Funds reported $88.8M of Astria Therapeutics stock for Q3 2022, up 417% quarter-over-quarter.
- 15 funds opened new Astria Therapeutics positions in Q3 2022 and 2 closed out, a net change of +13 holders.
- The largest Astria Therapeutics buyer in Q3 2022 was Vivo Capital, an estimated $6.7M added.
- The largest Astria Therapeutics seller in Q3 2022 was RA Capital Management, an estimated $2.28M sold.
Based on aggregated 13F filings for Q3 2022.